The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis
- 1 March 2008
- journal article
- clinical trial
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 67 (3) , 370-374
Abstract
Objective: To investigate the relationship between the magnitude of clinical response in the first 6 months of methotrexate (MTX) therapy and long-term outcome in children with juvenile idiopathic arthritis (JIA). Methods: The clinical charts of 125 JIA patients who were started with MTX and then followed for at least 5 years were reviewed. Based on the level of American College of Rheumatology (ACR) Pediatric response at 6 months, patients were divided in four mutually exclusive groups: (1) non-responders, (2) responders at 30%, (3) responders at 50%, and (4) responders at 70%. The long-term outcome in each response group was evaluated by calculating the percentage change in active and restricted joint counts from baseline to 1, 2 and 5 years and the frequency of inactive disease at 5 years. Results: At 6 months, 42 patients were classified as non-responders, 24 as 30% responders, 26 as 50% responders, and 33 as 70% responders. Patients who had achieved a 70% response showed a significantly greater percentage improvement in active joint count between baseline to 5 years compared with non-responders and 30% responders, and a significantly greater percentage improvement in restricted joint count between baseline to 5 years compared with 30% responders. The 70% responders also had a greater frequency of inactive disease at 5 years compared with 30% responders, Conclusions: Our results show that the achievement of an ACR Pediatric 70 response at 6 months after start of MTX therapy predicts a more favorable long-term outcome of patients with JIA.Keywords
This publication has 19 references indexed in Scilit:
- A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritisArthritis & Rheumatism, 2007
- A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexateArthritis & Rheumatism, 2004
- Are better endpoints and better design of clinical trials needed?Best Practice & Research Clinical Rheumatology, 2004
- Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritisArthritis & Rheumatism, 2003
- Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?Arthritis & Rheumatism, 1998
- Preliminary definition of improvement in juvenile arthritisArthritis & Rheumatism, 1997
- Reduction in long‐term disability in patients with rheumatoid arthritis by disease‐modifying antirheumatic drug–based treatment strategiesArthritis & Rheumatism, 1996
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Evaluation of response to methotrexate by a functional index in juvenile chronic arthritisClinical Rheumatology, 1995
- Development of a disability measurement tool for juvenile rheumatoid arthritis. The juvenile arthritis functional assessment report for children and their parentsArthritis & Rheumatism, 1991